enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

enVVeno Medical (NASDAQ:NVNO) regained compliance with Nasdaq Listing Rule 5550(a)(2) after its common stock maintained a closing bid of at least $1.00 for 10 consecutive business days, from January 20, 2026 through February 2, 2026. Nasdaq confirmed the matter is closed.

The company reported year-end cash and investments of approximately $28 million as of December 31, 2025 and said it has made meaningful progress on its 2026 strategic plans, with additional details expected in the coming weeks.

Positive

• Regained Nasdaq compliance after 10 consecutive business days ≥ $1.00 closing bid
• $28M cash and investments reported as of December 31, 2025

Negative

• None.

News Market Reaction

-8.21%

1 alert

-8.21% News Effect

On the day this news was published, NVNO declined 8.21%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Minimum bid price: $1.00 per share Compliance period: 10 business days Compliance window dates: Jan 20, 2026 – Feb 2, 2026 +5 more

8 metrics

Minimum bid price $1.00 per share Nasdaq Listing Rule 5550(a)(2) requirement

Compliance period 10 business days Consecutive days with closing bid at or above $1.00

Compliance window dates Jan 20, 2026 – Feb 2, 2026 Period Nasdaq cited for minimum bid compliance

Cash and investments Approximately $28 million Balance as of Dec 31, 2025 year-end

Current share price $10.23 Price before this compliance announcement

52-week high distance -94.8% Price vs 52-week high of $196.7

52-week low distance 8.6% Price vs 52-week low of $9.42

Relative volume 0.3x Today’s volume vs 20-day average

Market Reality Check

Price: $10.42 Vol: Volume 8,366 vs 28,069 20...

low vol

$10.42 Last Close

Volume Volume 8,366 vs 28,069 20-day average (relative volume 0.3x), indicating muted trading ahead of this news. low

Technical Shares at $10.23 are trading below the 200-day MA of $71.95 and about 94.8% below the 52-week high, sitting only 8.6% above the 52-week low.

Peers on Argus

NVNO was down 7.92% while peers showed mixed moves: INBS (-5.61%), AIMD (-3.14%)...

NVNO was down 7.92% while peers showed mixed moves: INBS (-5.61%), AIMD (-3.14%), XAIR (-0.86%) versus NXL (+1.59%) and ALUR (+2.27%). This pattern points to stock-specific dynamics rather than a broad sector rotation.

Historical Context

5 past events · Latest: Jan 15 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 15	Reverse stock split	Negative	-13.2%	Announced 1-for-35 reverse split reducing outstanding shares to about 655k.
Nov 26	Investor presentation	Neutral	-6.4%	CEO scheduled for virtual investor segment and Q&A on Dec 3, 2025.
Nov 13	FDA appeal outcome	Negative	-5.2%	FDA upheld not-approvable letter for VenoValve; focus shifted to enVVe.
Oct 31	Earnings and update	Positive	+1.1%	Reported Q3 2025 results with reduced net loss and cash runway commentary.
Sep 26	Regulatory discussion	Neutral	+1.2%	CEO discussed supervisory appeal to FDA after VenoValve not-approvable letter.

Pattern Detected

Recent news has often been followed by downside moves, particularly around structural actions and regulatory setbacks, with only modest positive reactions to operational or communication updates.

Recent Company History

Over the past several months, NVNO’s key events have centered on capital structure changes, regulatory outcomes, and investor communications. A reverse stock split announced on Jan 15, 2026 saw the stock fall 13.18%. Earlier, an unfavorable FDA appeal decision for VenoValve on Nov 13, 2025 coincided with a 5.16% drop. In contrast, third-quarter 2025 results on Oct 31, 2025 featuring a narrowed net loss led to a modest 1.1% gain. The current Nasdaq compliance news fits into this backdrop of managing listing status and regulatory challenges.

Market Pulse Summary

The stock moved -8.2% in the session following this news. The decline despite restored Nasdaq compli...

Analysis

The stock moved -8.2% in the session following this news. The decline despite restored Nasdaq compliance reflects lingering concerns around NVNO’s broader trajectory. Shares were already trading about 94.8% below the 52-week high and only 8.6% above the 52-week low. Past events, including an unfavorable FDA appeal and a reverse split, also saw negative reactions. While the company cited roughly $28 million in year-end cash, investors may remain focused on execution and prior regulatory setbacks.

Key Terms

minimum bid price

1 terms

minimum bid price financial

"which requires a minimum bid price of $1.00 per share."

The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.

AI-generated analysis. Not financial advice.

Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed

Reports Cash and Investments of approximately $28 million as of the Year Ended December 31, 2025

IRVINE, CA / ACCESS Newswire / February 4, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq confirmed that for the last 10 consecutive business days, from January 20, 2026 through February 2, 2026, the closing bid price of the Company's common stock was at or above $1.00, and as a result, the matter is now closed.

The Company has made meaningful progress on its 2026 strategic plans and expects to share additional details in the coming weeks. The Company believes that regaining compliance with listing requirements, combined with a year-end cash and investments balance of approximately $28 million as of December 31, 2025, positions it well for 2026.

About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.

Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775

MEDIA CONTACT:
Glenn Silver, FINN Partners
Glenn.Silver@finnpartners.com
(973) 818-8198

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

FAQ

What Nasdaq rule did enVVeno Medical (NVNO) regain compliance with on February 4, 2026?

enVVeno Medical regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement. According to the company, Nasdaq confirmed the stock closed at or above $1.00 for 10 consecutive business days from January 20, 2026 through February 2, 2026.

How long did NVNO need to maintain a $1.00 closing bid to regain Nasdaq compliance?

The company needed a 10 consecutive business day closing bid at or above $1.00 to regain compliance. According to enVVeno Medical, that period ran from January 20, 2026 through February 2, 2026, after which Nasdaq closed the matter.

How much cash and investments did enVVeno Medical (NVNO) report at year-end 2025?

enVVeno Medical reported approximately $28 million in cash and investments as of December 31, 2025. According to the company, this year-end balance is cited as supporting its position going into 2026 while it advances strategic plans.

What does Nasdaq closing the compliance matter mean for NVNO shareholders?

Nasdaq closing the matter means NVNO remains listed and avoids delisting proceedings tied to minimum bid price. According to enVVeno Medical, the company met the $1.00 threshold for the required 10 business days and the listing issue is considered resolved.